NVO Stock up on Plans to Advance Obesity Candidate Amycretin

Novo Nordisk NVO announced plans to advance amycretin, for weight management, into late-stage development. Amycretin is being developed for subcutaneous and oral administration.Shares of this Denmark-based company gained 2.95% on June 12, following the announcement.Oral amycretin is a novel, unimolecular co-agonist of both GLP-1 and amylin receptors being developed by...